NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") today announced that interim results from a Phase 1 trial studying Actimab-A in combination with CLAG-M have been accepted for presentation at the 2019 American Society of Hematology (ASH) annual meeting that is being held Dece

SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that its lead investigator, Dr

SEATTLE, Nov. 6, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib develo

BRIDGEWATER, N.J., Nov. 6, 2019 /PRNewswire/ -- Nestlé Health Science announced today the three winners of the tenth annual OPTIFAST® "New You" contest. The OPTIFAST® program is a medically-monitored, meal replacement weight loss program and the "New You" contest celebrates their achievements. The three winners were flown to

LEXINGTON, Mass., Nov. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that abstracts for both fimepinostat and CA-4948 were accepted for presentation at the 61st Annual Meeting of the American Society of Hematology (ASH) which will be

NEW HAVEN, Conn., Nov. 6, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or e

COSTA MESA, Calif., Nov. 6, 2019 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS), the preeminent provider of education and practice management services for orthopaedic surgeons and allied health professionals has entered a new partnership with CareCredit, a leading health, wellness and personal care credit card business.

- New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated patients - VANCOUVER, Nov. 6, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and co

Ms. Donna Parr and Dr. Niclas Stiernholm recruited to broaden public/private equity expertise TORONTO, Nov. 6, 2019 /PRNewswire/ - FACIT, a commercialization venture firm, reported on the expansion of its Executive-in-Residence program and new strategic initiatives. 

TARRYTOWN, N.Y., Nov. 6, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will share new and updated data for two investig